Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Top Cited Papers
- 9 September 2010
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 363 (11), 1005-1015
- https://doi.org/10.1056/nejmoa0907847
Abstract
Global control of tuberculosis is hampered by slow, insensitive diagnostic methods, particularly for the detection of drug-resistant forms and in patients with human immunodeficiency virus infection. Early detection is essential to reduce the death rate and interrupt transmission, but the complexity and infrastructure needs of sensitive methods limit their accessibility and effect. We assessed the performance of Xpert MTB/RIF, an automated molecular test for Mycobacterium tuberculosis (MTB) and resistance to rifampin (RIF), with fully integrated sample processing in 1730 patients with suspected drug-sensitive or multidrug-resistant pulmonary tuberculosis. Eligible patients in Peru, Azerbaijan, South Africa, and India provided three sputum specimens each. Two specimens were processed with N-acetyl-L-cysteine and sodium hydroxide before microscopy, solid and liquid culture, and the MTB/RIF test, and one specimen was used for direct testing with microscopy and the MTB/RIF test. Among culture-positive patients, a single, direct MTB/RIF test identified 551 of 561 patients with smear-positive tuberculosis (98.2%) and 124 of 171 with smear-negative tuberculosis (72.5%). The test was specific in 604 of 609 patients without tuberculosis (99.2%). Among patients with smear-negative, culture-positive tuberculosis, the addition of a second MTB/RIF test increased sensitivity by 12.6 percentage points and a third by 5.1 percentage points, to a total of 90.2%. As compared with phenotypic drug-susceptibility testing, MTB/RIF testing correctly identified 200 of 205 patients (97.6%) with rifampin-resistant bacteria and 504 of 514 (98.1%) with rifampin-sensitive bacteria. Sequencing resolved all but two cases in favor of the MTB/RIF assay. The MTB/RIF test provided sensitive detection of tuberculosis and rifampin resistance directly from untreated sputum in less than 2 hours with minimal hands-on time. (Funded by the Foundation for Innovative New Diagnostics.)Keywords
This publication has 22 references indexed in Scilit:
- Containment of Bioaerosol Infection Risk by the Xpert MTB/RIF Assay and Its Applicability to Point-of-Care SettingsJournal of Clinical Microbiology, 2010
- Evaluation of the Analytical Performance of the Xpert MTB/RIF AssayJournal of Clinical Microbiology, 2010
- Rapid Detection of Mycobacterium tuberculosis and Rifampin Resistance by Use of On-Demand, Near-Patient TechnologyJournal of Clinical Microbiology, 2010
- Molecular detection, identification and drug resistance detection inMycobacterium tuberculosis: Table 1FEMS Immunology & Medical Microbiology, 2009
- A Threshold Value for the Time Delay to TB DiagnosisPLOS ONE, 2007
- Facing the Crisis: Improving the Diagnosis of Tuberculosis in the HIV EraThe Journal of Infectious Diseases, 2007
- Technology for Automated, Rapid, and Quantitative PCR or Reverse Transcription-PCR Clinical TestingClinical Chemistry, 2005
- Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD InitiativeClinical Chemistry, 2003
- Detection of Rifampin Resistance in Mycobacterium tuberculosis in a Single Tube with Molecular BeaconsJournal of Clinical Microbiology, 2001
- Approximate Is Better than "Exact" for Interval Estimation of Binomial ProportionsThe American Statistician, 1998